DRD2 and Parkinson disease: Apomorphine, a non-specific D1 and D2 dopamine receptor agonist approved as an anti-Parkinsonism medication, has been extensively studied for dopamine receptor sensitivity and function [47], [48] and in treating alcohol dependence [49]–[51].